In May 2025, the New England Journal of Medicine published the first head-to-head clinical trial comparing two of the most effective anti-obesity medications on the market: tirzepatide (Zepbound) and semaglutide (Wegovy). This was the phase 3b open label extension of the SURMOUNT-5 clinical trial involving 751 non-diabetic obese patients. The main finding was that tirzepatide led to significantly more weight loss than semaglutide over 72
